Xenetic Biosciences, Inc.

menu

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Technology
    • Overview
    • XCART™ Platform
    • PolyXen®
    • Publications
  • Product Pipeline
    • Overview
    • XCART™
    • PolyXen®
  • News & Media
    • Press Releases
    • Presentations
    • Multimedia
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Financials
    • Financial Results
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Proxy Materials
    • Proxy Materials
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Governance Documents
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
News & Media

News & Media

  • Press Releases
  • Presentations
  • Multimedia

Press Releases

  • All News
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences to Host 2017 First Quarter Update Conference Call

May 9, 2017

Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston

May 1, 2017

Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston

Apr 20, 2017

Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer

Apr 4, 2017

Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update

Apr 3, 2017

Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017

Mar 29, 2017

Xenetic Biosciences Provides Update on Patent Portfolio Development

Mar 27, 2017

Xenetic Biosciences to Present at the 29th Annual ROTH Conference

Mar 9, 2017

Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia

Jan 6, 2017

Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer

Jan 4, 2017

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...11
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2021Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap